David S. Lowden Purchases 750 Shares of Diploma PLC (LON:DPLM) Stock

Diploma PLC (LON:DPLM) insider David S. Lowden acquired 750 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The stock was purchased at an average cost of GBX 3,928 ($50.85) per share, for a total transaction of £29,460 ($38,140.86).

Diploma Price Performance

Shares of DPLM opened at GBX 3,970 ($51.40) on Wednesday. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The company has a 50 day moving average price of GBX 4,385.96 and a 200-day moving average price of GBX 4,379.51. Diploma PLC has a fifty-two week low of GBX 3,372 ($43.66) and a fifty-two week high of GBX 4,808 ($62.25). The stock has a market capitalization of £5.30 billion, a PE ratio of 45.63, a PEG ratio of 2.82 and a beta of 0.75.

Diploma Increases Dividend

The business also recently announced a dividend, which was paid on Friday, January 31st. Shareholders of record on Thursday, January 16th were issued a dividend of GBX 42 ($0.54) per share. The ex-dividend date was Thursday, January 16th. This represents a yield of 0.93%. This is a positive change from Diploma’s previous dividend of $17.30. Diploma’s dividend payout ratio is currently 65.52%.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. increased their price target on Diploma from GBX 4,370 ($56.58) to GBX 4,420 ($57.22) and gave the stock a “neutral” rating in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, Diploma presently has an average rating of “Moderate Buy” and a consensus target price of GBX 4,567.50 ($59.13).

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.